Clinical Research Currents
  • Home
  • About Us
  • News
    • AI & Machine Learning
    • Alzheimers & Dementia
    • Animal studies
    • Clinical development
    • Clinical science
    • Contract Research Organization
    • Disparities
    • Education
    • Employment
    • FDA
    • FDA Guidance
    • FDA Guidance Documents
    • History
    • Immunotherapy
    • Innovation
    • International
    • Interview
    • Investigator
    • Mobile
    • NIH
    • Operations
    • Patient Perspective
    • Political economy
    • Pre-clinical
    • Precision Medicine
    • Recruitment
    • Regulatory
    • Study Design
    • Wearables
    • Trends
    • Real World Data/Evidence
    • Blockchain
    • Clinical trials
    • Adverse events
    • Technology
  • Calendar
  • Newsletter
  • Resources

2021 Update

Clinical Research Currents has temporarily suspended publication.
Learn about our new clinical trials startup, Sparrow Search, connecting patients with clinical trials.

Notable “trial flops of 2018”

www.biospace.com

December 7, 2018
Clinical development, Clinical trials

Ten notable “trial flops of 2018” included five Alzheimer’s trials and five in other conditions, and the majority failed due to lack of efficacy.  The developers of these drug candidates were big pharma companies –Merck & Co., Roche, Johnson & Johnson, Celgene, Takeda Pharmaceutical, Boehringer Ingelheim – as well as smaller companies including Incyte Corporation, eTV Therapeutics, Sarepta Therapeutics, and Alkermes. (BioSpace)

Clinical trials underestimate adverse events associated with immunotherapies

www.specialtypharmacytimes.com

December 7, 2018
Adverse events, Clinical trials, Oncology

An analysis of adverse events (AEs) associated with immune checkpoint inhibitors based on insurance claims suggests that the frequencies of immune-related AEs may be higher than reported in trials that led to the FDA approvals for immunotherapies. The researchers suggest that real world data could refine our expectations for outcomes beyond what is reported in clinical trials. (Specialty Pharma Times)

Facebook and Twitter talk could compromise clinical trial integrity

www.nature.com

December 7, 2018
Clinical trials

Patients are online, and they are talking about clinical trials. Social media interactions are allowing patients to make more informed choices about clinical trials, but the flow of information also has the potential to sway trial results when patients share study details. According to Craig Lipset of Pfizer, “It’s only a matter of time before Facebook jeopardizes the scientific integrity of a study.” (nature.com)

FDA developing guidance on patient engagement in medical device trials

www.medtechdive.com

December 7, 2018
Clinical trials, FDA Guidance, Patient Perspective

FDA’s Patient Engagement Advisory Committee (PEAC) is seeking public input to inform its draft guidance on developing patient-oriented medical device trials. This call for feedback is part of PEAC’s charter in 2017 to include patients in the device regulation process. The forthcoming FDA guidance intends to demystify patient engagement in the clinical trial process. (MEDTECHDIVE)

FDA will issue policies targeting “quality control” activities in clinical trials

www.acrpnet.org

December 7, 2018
Clinical trials, FDA, Operations

The U.S. Food and Drug Administration (FDA) will soon be issuing specific policies aimed at reducing the burdens associated with the conduct of clinical trials. These policies could target “quality control” activities in clinical trials, which, according to FDA Commissioner Scott Gottlieb, aren’t necessary in a digital age and add unnecessary workload and cost. (acrp.net)

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9

Subscribe to our Newsletter

Get the latest clinical research news delivered straight to your inbox each week.

Submit a Story

Do you have a story you'd like to feature on our website? Share it with us today!

Submit your story

 Join our LinkedIn Group

© 2023 Clinical Research Currents · All Rights Reserved